Inhibition of METTL3 ameliorates doxorubicin-induced cardiotoxicity through suppression of TFRC-mediated ferroptosis

Lin Wu,Yuxin Du,Litao Wang,Yingmei Zhang,Jun Ren
DOI: https://doi.org/10.1016/j.redox.2024.103157
IF: 11.4
2024-04-14
Redox Biology
Abstract:Background Doxorubicin (DOX) is a chemotherapeutic drug, while its clinical use is greatly limited by the life-threatening cardiotoxicity. N 6 -methyladenosine (m 6 A) RNA modification participates in varieties of cellular processes. Nonetheless, it remains elusive whether m 6 A modification and its methyltransferase METTL3 are involved in the progression of DOX-induced cardiotoxicity (DIC). Methods Mice were administrated with DOX (accumulative dosage of 20 mg/kg) repeatedly to establish a chronic DIC model. Cardiomyocyte-specific conditional METTL3 knockout mice were employed to evaluate the effects of altered m 6 A RNA modification on DIC. The effects of METTL3 on cardiomyocyte ferroptosis were also examined in response to DOX stimulation. Results DOX led to increased levels in m 6 A modification and METTL3 expression in cardiomyocytes in a c-Jun-dependent manner. METTL3 -knockout mice exhibited improved cardiac function, remodeling and injury following DOX insult. Besides, inhibition of METTL3 alleviated DOX-induced iron accumulation and ferroptosis in cardiomyocytes, whereas METTL3 overexpression exerted the opposite effects. Mechanistically, METTL3 promoted m 6 A modification of TFRC mRNA, a critical gene governing iron uptake, and enhanced its stability through recognition of the m 6 A reader protein, IGF2BP2. Moreover, pharmacological administration of a highly selective METTL3 inhibitor STM2457 effectively ameliorated DIC in mice. Conclusion METTL3 plays a cardinal role in the etiology of DIC by regulating cardiac iron metabolism and ferroptosis through TFRC m 6 A modification. Inhibition of METTL3 might be a potential therapeutic avenue for DIC.
biochemistry & molecular biology
What problem does this paper attempt to address?